Efficacy and risk assessment of long-term use of Pegcetacoplan-Empaveli

As an innovative targetedC3 therapy, the long-term effects and risk assessment of Pegcetacoplan (Pegcetacoplan) have always been the focus of clinical research. The approval of Empaveli was based on the results of the Phase 3 head-to-head study PEGASUS, which showed that Empaveli was significantly better than the traditional C5 inhibitor Soliris in improving hemoglobin levels and reducing the need for blood transfusions in patients with PNH.

In thePEGASUS study, the therapeutic effect of Empaveli was significantly better than that of Soliris, especially in the improvement of hemoglobin levels. The study showed that patients in the Empaveli treatment group had a statistically significant increase in hemoglobin levels of 3.84g/dL relative to baseline at 16 weeks (p < 0.0001). In contrast, patients in the Soliris treatment group did not show significant improvement in hemoglobin levels over the same time period. This result shows that Empaveli has a more significant therapeutic effect on PNH patients and can effectively increase hemoglobin levels and improve anemia symptoms.

In addition,Empaveli also showed excellent results in avoiding blood transfusions. During the 16-week treatment period, 85% of patients in the Empaveli group did not require blood transfusions, compared with only 15% of patients in the Soliris group. This result further proves the advantage of Empaveli in reducing the need for blood transfusions in PNH patients, and can help patients reduce the risk of long-term dependence on blood transfusions and improve their quality of life.

However,long-term use of Empaveli also carries certain risks, especially regarding the immune system. Although this drug can effectively inhibit the complement cascade and slow down the symptoms of immune diseases such as PNH, long-term use may cause some immune-related adverse reactions. For example, some patients may develop infections, allergic reactions, etc. Although these side effects are not serious in most patients, patients' health needs to be monitored regularly to ensure the safety of the treatment.

Reference materials:https://empaveli.com/